I know the study schedule has the 12 month report for first 5 patients due till the end of the year which could considerably impact on SP ( and of course company achievement) - which is 5-6 months and can be a long time and much can happen....looking more recently, the second group of subjects (patients) were implanted with valves (reported may 31) reported as being completed 'last week'....which is about 4 weeks ago (give or take)...and close to the 30 days for the first report for the second patient group. So, the 30 days report from the second group in the next few weeks, and the 12 month report for the first group around the same time as the (informal) 6 month report from the second group in about 6 months.......with the potential for FDA application.....it could be a very exciting 6 months .......... lots of news and steps closer to the end goal.
just my 2 cents worth.
- Forums
- ASX - By Stock
- AVR
- Ann: DurAVR First In Human Patient 6 Month Study Follow Up
AVR
anteris technologies global corp.
Add to My Watchlist
6.09%
!
$6.27

Ann: DurAVR First In Human Patient 6 Month Study Follow Up, page-13
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$6.27 |
Change
0.360(6.09%) |
Mkt cap ! $97.17M |
Open | High | Low | Value | Volume |
$5.93 | $6.30 | $5.91 | $107.9K | 17.39K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | $6.12 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.27 | 200 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 6.120 |
1 | 2000 | 6.100 |
1 | 1000 | 6.000 |
1 | 1250 | 5.950 |
1 | 857 | 5.830 |
Price($) | Vol. | No. |
---|---|---|
6.270 | 200 | 1 |
6.300 | 463 | 1 |
6.400 | 130 | 1 |
6.500 | 255 | 1 |
6.550 | 1092 | 1 |
Last trade - 15.42pm 27/06/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online